EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA

Painful Diabetic Neuropathy Clinical Trial

— EN21-01  

Official title:

EPPIC-Net EN21-01 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of 80 mg Daily of NRD135S.E1 Versus Placebo in Adult and Elderly Participants With Painful Diabetic Peripheral Neuropathy.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05480228
• Other study ID #: 2022P002381 (EN21-01)
• Secondary ID: OT2NS122680-01
• Status: Recruiting
• Phase: Phase 2
• Start date: September 21, 2022
• Est. completion date: January 31, 2025

Study information

• Verified date: April 2024
• Source: Massachusetts General Hospital
• Contact: Jean Mendez
• Phone: 617-548-4627
• Email: jmendez7[@]mgh.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety and efficacy of the current hard gelatin capsule formulation of NRD135S.E1 80 mg once daily in the treatment of PDPN when administered for 13 weeks.

Description:

This ISA describes a double-blind Phase II study of the PK/PD, safety, tolerability, and effect of 13 weeks of NRD135S.E1 (80mg/day) as an ISA within the context of the Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy, EN21-PP. The ISA is intended to be read and interpreted within the context of the Platform Protocol and focuses on the description of design features that are specific to NRD135S.E1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 122
• Est. completion date: January 31, 2025
• Est. primary completion date: January 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

ISA-Specific Inclusion Criteria (To be used in conjunction with Platform Protocol criteria.)

1. At the time of screening (V1) at least 40 mm on a 100-mm visual analog scale (VAS) for average pain over the previous 24 hours.

2. Patient-reported daily 11-point NRS (for average pain over the last 24 hours) meets the criteria specified in "Appendix B: Blinded Information" during both the 7-day screening and 7-day baseline periods. The algorithm will be assessed centrally. Waivers to the inclusion criteria will not be allowed. ISA-Specific Exclusion Criteria (To be used in conjunction with Platform Protocol criteria.) Participants fulfilling any of the following criteria are not eligible for the study.

1. Diagnosis of alcohol or substance abuse or dependence (other than nicotine or caffeine) within the 2 years before the Screening visit.

2. Moderate or severe renal impairment, known (documented) or defined as an estimated/calculated creatinine clearance/estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m2, according to the Chronic Kidney Disease Epidemiology Collaboration formula.

3. Any of the following conditions related to corrected QT intervals using Fridericia's

formula (QTcF):

1. A QTcF > 500 ms prior to starting IP.

2. A history of the following additional risk factors for torsade de pointes: heart failure, hypokalemia, history or family history of long QT syndrome.

4. History of myocardial infarction, other clinically active significant heart disease, or stroke.

5. Participants known to have participated in four or more studies for investigational pain drugs.

6. Participants known to be non-responders to more than three previous neuropathic pain medications at adequate doses over at least 4 weeks. Adequate doses (given as total daily doses) are defined as follows: 1,800 mg gabapentin; 300 mg pregabalin; opioid analgesics 60 mg oxycodone equivalent or 200 mg tramadol; 75 mg amitriptyline or equivalent tricyclic antidepressant; 60 mg duloxetine; 150 mg venlafaxine.

7. Known hypersensitivity or contraindication to any excipients of the study drug formulation.

8. Taking prohibited medications as described in Section 12, "Concomitant Therapy," and Appendix A, "Prohibited Medications."

9. Major depressive episode within the 6 months before screening and/or a history of diagnosed recurrent major depressive disorder within two years. Any of the following

conditions related to suicidality:

1. Any suicidal ideation with intent, with or without a plan, at screening, i.e., answering "yes" to questions 4 or 5 on the Suicidal Ideation section of the Baseline/Screening version of the Columbia-Suicide Severity Rating Scale (C-SSRS);

2. Answering "yes" on any item of the Suicidal Behavior Section (except for the "non-suicidal self-injurious behavior") of the C-SSRS if this behavior occurred in the past 2 years;

3. A lifetime history of suicide attempt (V1).

10. Previous known or possible exposure to NRD135S.E1. Waivers to the exclusion criteria will not be allowed.

Related Conditions & MeSH terms

• Diabetic Neuropathies
• Pain
• Painful Diabetic Neuropathy
• Peripheral Nervous System Diseases

Intervention

Drug:
• NRD135SE.1
The double-blind treatment phase is up to 13 weeks.

Other:
• Placebo
A matching placebo will be taken for up to 13 weeks.

Locations

Country	Name	City	State
United States	MGH Department of Anesthesia, Critical Care, and Pain	Boston	Massachusetts
United States	Northwestern Department of Neurology	Chicago	Illinois
United States	South Lake Pain Institute	Clermont	Florida
United States	Healthcare Research Network (Flossmoor)	Flossmoor	Illinois
United States	SIMEDHealth LLC	Gainesville	Florida
United States	University of Florida	Gainesville	Florida
United States	Healthcare Research Network (Hazelwood)	Hazelwood	Missouri
United States	University of Wisconsin	Madison	Wisconsin
United States	Columbia University Medical Center/Neurological Institute	New York	New York
United States	Mount Sinai School of Medicine	New York	New York
United States	University of Pittsburgh	Pittsburgh	Pennsylvania
United States	VCU Department of Neurology	Richmond	Virginia
United States	University of Rochester	Rochester	New York
United States	University of Utah School of Medicine	Salt Lake City	Utah
United States	University of California, San Diego	San Diego	California
United States	University of Washington	Seattle	Washington

Sponsors (4)

Lead Sponsor	Collaborator
James P. Rathmell, MD	Icahn School of Medicine at Mount Sinai, National Institute of Neurological Disorders and Stroke (NINDS), New York University

Country where clinical trial is conducted

United States, 

References & Publications (4)

Dworkin RH, Turk DC, Peirce-Sandner S, McDermott MP, Farrar JT, Hertz S, Katz NP, Raja SN, Rappaport BA. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain. 2010 Jul;150(1):12-16. doi: 10.1016/j.pain.2010.02.002. Epub 2010 Mar 3. No abstract available. — View Citation

Tarpey T, Petkova E, Ciarleglio A, Ogden RT. Extracting scalar measures from functional data with applications to placebo response. Stat Interface. 2021;14(3):255-265. doi: 10.4310/20-sii633. — View Citation

Tarpey T, Petkova E, Lu Y, Govindarajulu U. Optimal Partitioning for Linear Mixed Effects Models: Applications to Identifying Placebo Responders. J Am Stat Assoc. 2010 Jan 1;105(491):968-977. doi: 10.1198/jasa.2010.ap08713. — View Citation

Van Buuren, S., & Groothuis-Oudshoorn, K. (2011). Journal of Statistical Software mice: Multivariate Imputation by Chained Equations in R (Vol. 45). http://www.jstatsoft.org/

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to Pain Catastrophizing Scale - Short Form 6 (PCS-SF6)	Catastrophizing is a pain-specific psychosocial construct comprising cognitive and emotional processes such as helplessness, pessimism, rumination about pain-related symptoms, and magnification of pain reports. The PCS-SF6 is a 6-item, self-report measure of catastrophic thinking associated with pain. Scores range from 0-24, with higher scores indicating more catastrophizing.	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the Pain, Enjoyment, and General activity scale (PEG).	The PEG is a three-item (each scored 0-10) multidimensional pain measure designed and validated for use in primary care and other ambulatory clinic patients, as a practical and useful tool to improve assessment and monitoring of chronic pain in primary care.	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the PROMIS Physical Functioning Short-Form 6b	The Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Functioning short form is a 6-item scale that is widely used in pain research. It is a unidimensional scale that shows broad coverage of the physical function construct, good construct validity, and high levels of temporal stability. The PROMIS Physical Function Scale is expressed as a T-score, with a population mean of 50 and SD of 10. Higher scores represent better physical functioning; possible T scores in this distribution range from 21 to 59 (PROMIS, 2020).	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the Pain Health Questionnaire (PHQ-2).	The 2-item PHQ-2 is a brief depression screening tool that correlates strongly with PHQ-9 scores and shows good sensitivity for identifying individuals with depressive disorders in the general population in a variety of medical samples. Scores range from 0-6, with higher scores indicating more depressive symptomatology.	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the Generalized Anxiety Disorder - 2 item scale (GAD-2).	The GAD-2 is a 2-item screening tool that is widely used to screen for clinically significant anxiety symptoms and anxiety disorders in clinical settings. It shows good sensitivity and specificity as a screening tool for anxiety disorders. Scores range from 0-6, with higher scores indicating more anxiety symptomatology.	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the Tobacco, Alcohol, Prescription medication, and other Substance use Tool (TAPS-1).	The TAPS-1 is the screening component of the TAPS tool and consists of a single stem question with four items covering the frequency of past-12-month use of tobacco, alcohol, and illicit drugs, and non-medical use of prescription medications. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use. The TAPS-1 shows good sensitivity and specificity for identifying substance use disorders.	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the PROMIS Sleep Disturbance - 6A.	The PROMIS Sleep Disturbance short form is a convenient 6-item scale that correlates strongly with the longer forms. The PROMIS Sleep Disturbance Scale is expressed as a T-score, with a population mean of 50 and standard deviation (SD) of 10. Possible T scores in this distribution range from 31.7 to 76.1 (PROMIS, 2021).	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the Sleep Duration Scale.	A single-item scale measuring the duration of actual sleep a participant has gotten, on average, over the past month. Numerical responses will be provided in hours and minutes.	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the Opioid Use Questionnaire (OUQ).	The OUQ is an indicator of past or present use of any of the listed opioid medications. There are a total of three yes/no items where a yes indicates the use of such medications.	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the Patient Global Impression of Change (PGIC).	The PGIC is a single-item measure of patient-reported improvement that is widely used as a general outcome measure in studies of chronic pain patients. It is often used as an index of treatment-associated change, and patient-reported improvements in the form of PGIC scores correlate robustly with significant improvement in pain intensity, pain interference with activities of daily living, mood, and quality of life (Perrot and Lanteri-Minet, 2019).	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the Norfolk Quality of Life - Diabetic Neuropathy (Norfolk QOL-DN)	The Norfolk QOL-DN is a validated 47-item, patient-reported outcome measure, sensitive to the different features of diabetic neuropathy (DN) including small fiber, large fiber, and autonomic function. A higher score indicates higher levels of neuropathic pain.	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the Neuropathy examination.	The neuropathy examination will be a single procedure consisting of visual inspection of the feet, brief distal motor exam, ankle and knee deep tendon reflexes, and a standardized sensory exam. This exam will collect the data needed to calculate several common scores including: the Michigan Neuropathy Screening Instrument (MNSI) Part B, the Utah Early Neuropathy Scale (UENS) and the Toronto Clinical Scoring System (TCNS). The MSNI Part B consists of visual inspection of the feet and assessment of ankle reflexes, vibration sense, and monofilament testing. The TCNS is quantitative scoring system for evaluating the severity of peripheral neuropathy. Most of the test is done on or near the toes, light touch testing is done with a 10gm monofilament fiber. The UENS consists of testing the distal lower extremities for motor function, sharp sensation, allodynia, vibration sensation, and deep tendon reflexes. It is scored on a scale of 0-42 where zero is normal.	13 weeks
Other	To assess the effect of NRD135S.E1 in comparison to placebo with respect to the actigraphy step count.	Mean daily step counts will be used as an index of physical activity.	13 weeks
Primary	To demonstrate that NRD135S.E1 80 mg daily is superior to placebo in relieving neuropathic pain associated with PDPN, after 13 weeks' treatment.	Change from Baseline to Week 13 in the weekly mean of the daily 24-hour average pain measured by Numeric Rating Scale (NRS) (abbreviated herein as WAP for weekly average pain). The NRS is a 0-10 scale, with 0 indicating no pain, and 10 being the worst possible pain.	13 weeks
Primary	The frequency (i.e. number of participants) with treatment emergent adverse events (TEAEs) reported in the time period defined by first administration of IP until 7 days after the last dose of IP.	A treatment-emergent adverse event (TEAE) is any AE temporally associated with the use of study treatment whether or not considered by the investigator as related to study treatment.	13 weeks
Secondary	Occurrence of 30% reduction of WAP from Baseline to Week 13.	Weekly Average Pain is abbreviated as WAP.	13 weeks
Secondary	Occurrence of 50% reduction of WAP from Baseline to Week 13.	Weekly Average Pain is abbreviated as WAP.	13 weeks